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A comparison of 692 early invasive breast cancer with, and 1564 without, a family history of breast cancer showed that the former
were younger at diagnosis (P¼0.002), had smaller tumours (P¼0.012), were more frequently oestrogen receptor positive
(P¼0.006) and diagnosed preclinically (Po0.001).
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A long recognised risk factor for breast cancer is a family history of
the disease, although the majority of affected women do not have
an affected close relative, and only 5–10% do have a true hereditary
predisposition (Carter, 2001). The overall risk of developing breast
cancer is 1.9–3.9 times higher in women with an affected mother or
sister (Collaborative Group on Hormonal Factors in Breast Cancer,
2001), but only a few studies have investigated the characteristics of
breast cancer in women with a family history. We analysed the
pathological, biological and clinical features of breast cancer in
patients with (FHþ) and without (FH ) a family history of breast
cancer, the former being further subdivided into those with an
affected first- or second-degree relative.
MATERIALS AND METHODS
A total of 2256 women with early invasive operable breast cancer,
who underwent surgery at Verona Hospitals between January 1992
and April 2001, were asked at their first visit whether they had any
first- or second-degree relatives who had had breast cancer. Our
analysis first compared those reporting at least one affected
relative (FHþ) with those reporting no affected relative (FH );
subsequently, the FHþ patients were divided into those with at
least one first-degree relative (1st DFH) and those with only
second-degree relatives with breast cancer (2nd DFH): only first-
and second-degree relatives were considered in order to reduce
ascertainment bias. Answers were always checked at the sub-
sequent visit (at the time of the first cycle for the patients receiving
chemotherapy, after 3 months for the others).
All of the patients were assigned a UICC pathological TNM
stage. On the basis of pathologist-defined tumour size, patients
were divided into three categories: pT1 (o2cm), pT2 (2–5cm)
and pT3 (45cm); the number of pathologically positive axillary
nodes was divided into none, o3, 4–10 and 410; tumour grading
was recorded as G1 (well differentiated), G2 (moderately
differentiated) or G3 (undifferentiated).
Immunohistochemistry (IHC) defined oestrogen (ER) and
progesterone receptor (PgR) status and was considered positive
if more than 10% of the cells were stained for either. The
replicative cell fraction was IHC stained using the Ki-67
monoclonal antibody (Mab-DAKO-PC); given the lack of an
accepted cutoff point, the results were arbitrarily classified as low,
medium or high (p10%, 11–25% or 425% of stained cells). C-
erbB-2 levels were determined by IHC using the DAKO-PC
monoclonal antibody, and considered positive if at least one cell
was stained.
At their first visit to the Department of Medical Oncology, all
patients were asked about their disease presentation and divided
into those who underwent mammography and ultrasonography
because of breast discomfort or a lump (symptomatic) and those
without any subjective symptoms (asymptomatic). A public
screening programme has been active in Verona since July 1999,
before which 30% of our patients had undergone mammography
and ultrasonography even in the absence of subjective symptoms.
For the analysis of the pathological, biological and clinical
differences by age at diagnosis, the patients were arbitrarily
divided into seven age groups (o35, 36–45, 46–55, 56–65, 66–75,
76–85 and 485 years).
The w
2 test was used to compare the prevalence of FHþ (1st and
2nd DFH) and FH  women in relation to all the variables.
As it is known that younger women have a higher risk associated
with a family history, an age-adjusted analysis was made to
compare the prevalence of FHþ women across the categories of
the other considered variables.
Significance was tested using the likelihood ratio statistic and a
significance level of 0.05.
RESULTS
The overall prevalence of FHþ women was 30.7% (692), of whom,
356 (51.4%) were classified as 1st DFH and 336 (48.6%) as 2nd
DFH. Table 1 shows the crude and age-adjusted prevalence of
FHþ women across the various categories. Family history was
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ysignificantly associated with tumour size, ER, age at diagnosis and
disease presentation. No significant association was found between
family history and nodal involvement, PgR, Ki-67 status, grading
or c-erb B2 levels (Table 1).
Associations with degree of familial relationship were investi-
gated only for the variables significantly associated with a family
history when a more general definition was used (tumour size, ER,
age at diagnosis and disease presentation). Only age at diagnosis
was significant (w
2¼36.0; Po0.001): older women were more
likely to have a first-degree relative (76.1% of those aged 474
years had an affected first-degree relative vs 51.9% of those aged
45–74 and 33.0% of those aged o45 years; data not shown).
DISCUSSION
A positive family history is now an established risk factor for
breast cancer, but few studies have focused on the characteristics
of breast cancer in FHþ women. We have done so because
physicians can rarely study genetic patterns in clinical practice,
and must therefore rely on patient-supplied FH reports despite
their possible inaccuracy (Slattery and Kerber, 1993; Eerola et al,
2000). Furthermore, some tumours will develop in relatives after
the patient has been examined.
We have only considered first- and second-degree relatives, the
percentages of which were similar to those reported in other
studies (Collaborative Group on Hormonal Factors in Breast
Cancer, 2001). Our adjusted results suggest significant differences
in FHþ tumours, which seem to be smaller, more often ERþ, and
more likely to be diagnosed at a younger age and at an
asymptomatic stage. The published data are few and inconsistent,
and usually not subject to multivariate analysis adjusted for age; in
fact, only Kreiger about receptor status (Kreiger et al, 1991) and
Swede about c-erbB2 (Swede et al, 2001) compared FH with
clinical and pathological characteristics in a multivariate analysis
adjusted for age as in this paper. Most have not found any
Table 1 Correlation between breast cancer characteristics in patients with and without FH
P-value P-value
FH  no.
a FH+ (1st degree) no.
b FH+/total % Raw Adjusted
c
pTumour size 0.006 0.012
T1 1036 502 (262) 32.6
T2 495 173 (85) 25.9
T3 33 17 (9) 34.0
No. of positive nodes 40.5 40.5
0 947 412 (205) 30.3
1–3 360 159 (82) 30.6
4–10 135 66 (31) 32.8
410 63 27 (14) 30.0
ER 0.021 0.006
Negative 284 99 (48) 25.8
Positive 1199 561 (288) 31.9
PgR 0.211 0.264
Negative 511 222 (104) 30.3
Positive 799 394 (206) 33.0
Proliferative index 0.105 0.073
Ki-67¼0–15% 828 400 (205) 32.6
Ki-67¼16–25% 311 140 (74) 31.0
Ki-67¼26–100% 276 101 (47) 26.8
Grading 0.476 0.397
G1 165 79 (39) 32.4
G2 691 320 (168) 31.7
G3 369 150 28.9
C-erb B2 status 0.107 0.065
Negative 427 239 (117) 35.9
Positive 298 135 (69) 31.2
Age at diagnosis (years) 0.002 —
p35 32 19 (6) 37.3
35–44 190 84 (28) 30.7
45–54 371 201 (107) 35.1
55–64 376 184 (84) 32.9
65–74 373 137 (80) 26.9
75–84 185 51 (38) 21.6
X85 37 16 (13) 30.2
Disease presentation o0.001 o0.001
Asymptomatic 502 302 (144) 37.6
Symptomatic 1013 372 (198) 26.9
ER¼oestrogen receptors; PgR¼progesteron receptors.
aNo family history of breast cancer.
bFamily history of breast cancer.
cP-value adjusted for age at diagnosis.
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patients (Fukutomi et al, 1993; Israeli et al, 1994; Tsuchiya et al,
1998; Russo et al, 2002), whereas Mohammed observed a trend
(Mohammed et al, 1998) and Colditz reported a higher percentage
of T1 in women FHþ (60%) vs FH  (54%) (Colditz et al, 1993).
There were no significant differences in nodal involvement
between our FH  and FHþ tumours. Some studies (Fukutomi
et al, 1993; Mohammed et al, 1998) reported that FHþ patients
were more likely to have tumours with fewer nodal metastasis, but
others (Ruder et al, 1988; Israeli et al, 1994; Tsuchiya et al, 1998;
Russo et al, 2002) found no significant difference.
Our univariate and multivariate analyses showed that
FHþ tumours are more likely to be ERþ, but there were no
statistically significant differences in PgR, Ki-67 or grading. Some
studies found that FHþ tumours are more likely to be ER  and
PgR  (Kreiger et al, 1991; Huang et al, 2000), have a higher
proliferation rate (Marcus et al, 1994) and higher grading
(Mohammed et al, 1998), but none of the others found any
differences (Fukutomi et al, 1993; Israeli et al, 1994; Tsuchiya et al,
1998; Russo et al, 2002).
In agreement with others (Fukutomi et al, 1993; Swede et al,
2001), we did not find any differences in relation to the more
recent c-erbB2 marker.
Our FHþ tumours were more frequently diagnosed in an
asymptomatic phase than the FH  tumours. This is probably due
to the greater sensitisation induced by having one or more affected
relatives, which encourages asymptomatic women to undergo
diagnostic investigations; our data are similar to those of others
(Colditz et al, 1993; Murabito et al, 2001) who have observed that
FHþ women undergo more mammographies.
Our FHþ patients were younger at diagnosis, which confirms
some previous data (Israeli et al, 1994), but not others (McCredie
et al, 1997; Tsuchiya et al, 1998; Russo et al, 2002).
In conclusion, FHþ seems to be associated with an asympto-
matic diagnosis (and therefore smaller and ERþ tumours),
possibly because of the more intensive use of mammography or
differences in biological behaviour. FHþ patients are younger,
although it is not clear as to whether this reflects a truly earlier
disease onset or an earlier diagnosis due to the more intensive use
of mammography.
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